MSDC-0602K

Research use only, not for human use.

MSDC-0602K (Azemiglitazone potassium) (Azemiglitazone potassium) is a PPARγ-sparing thiazolidinedione (Ps-TZD) compound that binds to PPARγ with an IC50 of 18.25 μM.

Azemiglitazone potassium (MSDC-0602K), a PPARγ-sparing thiazolidinedione (Ps-TZD), binds to PPARγ with the IC50 of 18.25 μM. Azemiglitazone potassium modulates the mitochondrial pyruvate carrier (MPC). Azemiglitazone potassium can be used for the research of fatty liver including dysfunctional lipid metabolism, inflammation, and insulin resistance. Azemiglitazone potassium, an insulin sensitizer, improves insulinemia and fatty liver disease in mice, alone and in combination with Liraglutide.

——

Diabetic db/db and MS-NASH mice are treated with Azemiglitazone potassium by oral gavage, Liraglutide by s.c. injection, or combination Azemiglitazone potassium + Liraglutide. This combination treatment may be an effective therapeutic strategy for diabetes and non-alcoholic steatohepatitis (NASH).Animal Model:Five-week-old male db/db mice on C57BL/6J background and age/sex-matched db/+ control mice Dosage:30 mg/kg MSDC-0602K; 0.2 mg/kg Liraglutide Administration:MSDC-0602K gavage daily, Liraglutide s.c. injection every other day, or combined MSDC-0602K+ Liraglutide Result: MSDC-0602K corrected glycemia and reduced insulinemia when given alone, or in combination with Liraglutide. However, MSDC-0602K + Liraglutide combination more significantly improved glucose tolerance and liver histology.

——

Metabolic Enzyme/Protease

PPAR

PPAR

——

——

1314533-27-1

409.5

C19H16KNO5S

>98% (HPLC)

In Vitro:?DMSO : 250 mg/mL (610.50 mM; Ultrasonic )

COC1=CC=CC(=C1)C(=O)COC2=CC=C(C=C2)CC3C(=O)[N-]C(=O)S3.[K+]

——

(-20℃)

With Ice Pack

≥ 2 years